Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021.
For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss CodeBreak 100, a phase 1/2 study evaluating the safety, tolerability, PK, and efficacy of Sotorasib (AMG 510) in patients with solid tumors with a specific KRAS mutation.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.